Oppenheimer Issues Positive Forecast for Guardian Pharmacy Services (NYSE:GRDN) Stock Price

Guardian Pharmacy Services (NYSE:GRDN) had its price objective hoisted by Oppenheimer from $38.00 to $43.00 in a research report released on Thursday,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

A number of other research analysts also recently weighed in on GRDN. Bank of America initiated coverage on Guardian Pharmacy Services in a research note on Monday, April 27th. They issued a “buy” rating and a $42.00 price target for the company. Truist Financial raised their price target on Guardian Pharmacy Services from $38.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Raymond James Financial restated an “outperform” rating and issued a $40.00 price target on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Zacks Research upgraded Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 18th. Finally, Wall Street Zen upgraded Guardian Pharmacy Services from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Guardian Pharmacy Services presently has an average rating of “Buy” and an average price target of $41.33.

Guardian Pharmacy Services Stock Performance

NYSE:GRDN opened at $36.01 on Thursday. The company has a market cap of $2.28 billion, a PE ratio of 43.38, a PEG ratio of 2.43 and a beta of 0.09. Guardian Pharmacy Services has a 52-week low of $19.17 and a 52-week high of $41.36. The stock has a 50-day simple moving average of $36.07 and a 200 day simple moving average of $32.28.

Guardian Pharmacy Services (NYSE:GRDN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. The business had revenue of $336.60 million during the quarter, compared to the consensus estimate of $329.89 million. Guardian Pharmacy Services had a return on equity of 32.07% and a net margin of 3.64%.Guardian Pharmacy Services’s quarterly revenue was up 2.2% on a year-over-year basis. During the same period last year, the company earned $0.22 earnings per share. On average, research analysts predict that Guardian Pharmacy Services will post 1.17 earnings per share for the current fiscal year.

Insider Activity at Guardian Pharmacy Services

In other news, insider Kendall Forbes sold 346,672 shares of Guardian Pharmacy Services stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $10,289,224.96. Following the completion of the transaction, the insider directly owned 453,256 shares in the company, valued at approximately $13,452,638.08. The trade was a 43.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director William E. Bindley sold 3,570,677 shares of Guardian Pharmacy Services stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $105,977,693.36. Following the transaction, the director owned 4,469,316 shares of the company’s stock, valued at $132,649,298.88. This represents a 44.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 9,726,405 shares of company stock worth $288,679,700 in the last three months. 32.96% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. State of Alaska Department of Revenue bought a new position in shares of Guardian Pharmacy Services during the 3rd quarter worth approximately $30,000. Ameritas Investment Partners Inc. boosted its stake in shares of Guardian Pharmacy Services by 26.5% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after acquiring an additional 345 shares during the period. Raymond James Financial Inc. bought a new position in shares of Guardian Pharmacy Services during the 2nd quarter worth approximately $43,000. Strs Ohio acquired a new stake in Guardian Pharmacy Services during the 4th quarter worth approximately $75,000. Finally, Clearstead Advisors LLC lifted its holdings in Guardian Pharmacy Services by 196.3% during the 4th quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock worth $79,000 after purchasing an additional 1,741 shares during the last quarter.

Key Stories Impacting Guardian Pharmacy Services

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Positive Sentiment: Q1 results topped estimates — EPS and revenue beat consensus, net income rose year-over-year and residents served increased ~10%, showing continued top-line resilience. GRDN Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Analyst upgrade/price-target lift — Oppenheimer raised its target to $43 with an “outperform” rating, signaling institutional conviction and ~19% upside from current levels. Benzinga Coverage
• Neutral Sentiment: Annual meeting votes passed — shareholders backed directors, executive pay and the auditor, removing a potential governance overhang. Guardian Pharmacy Stockholders Back Directors, Pay and Auditor
• Neutral Sentiment: Full-year revenue guidance roughly in line with Street — the company updated FY guidance (revenue near ~$1.4B), so expectations weren’t materially raised; that limits upside from guidance alone. Business Wire: Q1 Results & Guidance
• Negative Sentiment: IRA pricing reset is pressuring margins — management guided adjusted EBITDA to about $123M–$127M and cited impacts from the Inflation Reduction Act drug-pricing changes, which likely explains the sell-off as investors reassess near-term profitability. Guardian Pharmacy Services forecasts $123M-$127M adjusted EBITDA amid IRA pricing reset
• Negative Sentiment: Market reaction: elevated volume and a price decline — the mixed print (beats but constrained EBITDA and conservative guidance implications) has prompted short-term selling as investors weigh growth vs. policy-driven margin risk. MarketBeat GRDN Quote

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.